Given the emerging roles of ARID1A in the DNA damage response [13], accumulating evidence has enhanced our understanding of the biological role of ARID1A, offering new mechanisms for synthetic lethality-based targeting of ARID1A-inactivated cancers, such as inhibition of PARP [71,72] and ATR [73]. The gene discussed is ATR; the disease is cancer.